(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 69.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Ascendis Pharma A's revenue in 2025 is $418,978,409.On average, 7 Wall Street analysts forecast ASND's revenue for 2025 to be $50,246,889,730, with the lowest ASND revenue forecast at $47,006,435,261, and the highest ASND revenue forecast at $54,673,338,154. On average, 7 Wall Street analysts forecast ASND's revenue for 2026 to be $88,498,320,286, with the lowest ASND revenue forecast at $75,269,529,357, and the highest ASND revenue forecast at $113,024,459,220.
In 2027, ASND is forecast to generate $123,935,882,777 in revenue, with the lowest revenue forecast at $96,268,698,754 and the highest revenue forecast at $155,660,037,627.